BANK VONTOBEL/CALL/BIOGEN IDEC/330/0.1/20.09.24 | Delayed Deutsche Boerse AG 04:34:18 2024-06-03 EDT | ||
| 0.059 EUR | -18.06% |
|
| 1 month | +213.04% | ||
| 3 months | -55.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 0.059 | -18.06% |
| 24-05-31 | 0.072 | +41.18% |
| 24-05-30 | 0.051 | +121.74% |
| 24-05-29 | 0.023 | -42.50% |
| 24-05-28 | 0.04 | +11.11% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 04:34 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM36AW |
| ISIN | DE000VM36AW4 |
| Date issued | 2023-10-18 |
| Strike | 330 $ |
| Maturity | 2024-09-20 (110 Days) |
| Parity | 10 : 1 |
| Emission price | 1.65 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.99 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.021 € |
| Spread % | 26.25% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Warrants
- Warrant
